BP lowering and cardiovascular risk reduction

Area of Science:

• Cardiovascular Medicine
• Clinical Pharmacology
• Epidemiology

Background:

• Hypertension is a major risk factor for cardiovascular disease (CVD).
• Evidence for the net benefit of blood pressure lowering treatment (BPLT) across the full spectrum of blood pressure is debated.
• Previous meta-analyses have not fully addressed the magnitude of benefit across varying blood pressure levels.

Purpose of the Study:

• To quantify the effects of BPLT on primary and secondary CVD prevention.
• To assess how the benefits of BPLT vary with baseline blood pressure levels.
• To provide evidence for optimizing BPLT strategies.

Main Methods:

• Individual participant-level data meta-analysis of randomized controlled trials.
• Included trials focused on BPLT for primary and secondary CVD prevention.
• Analysis stratified by baseline systolic blood pressure (SBP) categories.

Main Results:

• BPLT significantly reduced the risk of major cardiovascular events in both primary and secondary prevention.
• The proportional risk reduction was consistent across different SBP levels.
• The absolute risk reduction was substantially greater in individuals with higher baseline SBP.

Conclusions:

• Pharmacological BPLT is beneficial for both primary and secondary CVD prevention.
• Higher baseline blood pressure is associated with greater absolute benefits from BPLT.
• These findings support the use of BPLT even in individuals with moderately elevated blood pressure.